Nanogen, Fisher Scientific expand R&D collaboration

Aug. 4, 2006 – Nanogen Inc., a San Diego developer of advanced diagnostic products, and Fisher Scientific International Inc. of Hampton, N.H., announced that the companies have expanded their relationship to include a research and development collaboration in molecular diagnostics. The companies said the collaboration agreement complements Fisher’s equity investment in Nanogen announced in March 2006.

Nanogen and Fisher agreed to share technology and patent rights specifically for the development, manufacture and marketing of new molecular diagnostic products. Under the agreement, Fisher Scientific may provide up to $10 million in total during 2007 and 2008 for the research and development of infectious disease and molecular diagnostic tests that will be mutually agreed upon. The intention is that knowledge, intellectual property and capabilities of both companies will enable molecular diagnostic products to be brought to the market more quickly.

In addition, Nanogen and Athena Diagnostics, a wholly owned subsidiary of Fisher Scientific International, have agreed to develop, manufacture and market products based on Athena’s proprietary biomarkers for research and for in vitro diagnostic use.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.